Business Wire

REE Cooperates with Hino Motors to Showcase New FlatFormer Concept Vehicle at the 46th Tokyo Motor Show

23.10.2019 09:30:00 EEST | Business Wire | Press release

Share

Tokyo Motor Show – Today, REE announced its cooperation with Hino Motors, a leading provider of commercial vehicles, and showcased its technology within Hino’s new FlatFormer modular concept model, a super-flexible chassis that optimizes electric mobility solutions, at the 46th Tokyo Motor Show.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191022006241/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

REE’s corner module technology plays an important role to the FlatFormer concept design. FlatFormer leverages REE’s unique technology, which allows the entire drive components to reside within the wheel housing, thus creating a fully flat chassis.

With the contribution of REE’s novel electric solution, Hino’s light duty FlatFormer chassis delivers optimized space, flexibility and energy efficiency to customers. [SO2] It supports a diverse range of plug-and-play body configurations that optimize internal vehicle space and provide room for additional in-car batteries and advanced safety technologies.

“It was a wonderful opportunity to cooperate and build FlatFormer together with REE, which we unveiled at Tokyo Motor Show 2019,” said Mr. Akira Yamaguchi, the General Manager of the design division at Hino Motors. “REE and Hino share the same vision of creating a sustainable and vividly prosperous future and reinventing the concept of mobility to deliver new value.”

“REE is on a mission toward widespread sustainable and modular electrified mobility, and we’re honored to showcase the results of our cooperation with Hino’s team at this year’s event,” said Daniel Barel, Co-Founder and CEO of REE. “REE’s goal is to enable Hino’s future plan with more space in a smaller footprint with full compatibility with their advanced chassis.[SO3] REE’s modular corner technology works seamlessly within the FlatFormer allowing for a flat chassis configuration. Hino Motors is our first Japanese relationship in the commercial market, and we are extremely excited and humbled by this opportunity to collaborate and be part of this joint journey towards a new electric mobility future.”

REE’s fully modular corner supports any size EV and enables rapid e-mobility market innovation by significantly simplifying and expediting model development cycles. Japan is a leader in the e-mobility arena, and REE was fortunate to work together with Million Steps, a business development firm that extends the reach of Israeli companies throughout Japan, to bring this cooperation to fruition.

FlatFormer demonstrations are available at Hino’s booth at the Tokyo Motor Show, Aomi Exhibition Hall A, Tokyo Big Sight, from the 24th of October through the 4th of November.

About REE

REE is fundamentally reinventing the way in which vehicles are built through best-in-class technologies and an innovative design. The company’s architecture solution integrates the motors, steering, suspension, drivetrain, sensing, brakes, thermal systems, and power management into the wheel well. By concentrating all drive components into such a small footprint, REE offers a completely flat and modular chassis that allows optimal design flexibility and multiple body configurations on a single platform. This unique approach reduces vehicle space and weight, increases efficiency and allows manufacturers to easily redesign and repurpose vehicles to meet radically shifting automotive and commercial vehicle needs, this significantly reducing their capital expenditures. REE’s solution is set to be crucial to the electrification process and will play a key role in shaping the future of mobility. REE was founded by Daniel Barel and Ahishay Sardes. More information about REE can be found at: www.ree.auto.

About Hino Motors:

Founded in 1942, Hino is a global automotive company of commercial vehicles, with the corporate mission of contributing to a better world and future by supporting the mobility of people and goods. By offering the optimal truck and bus for each and every driver, Hino supports the life of people around the world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Anthony Jean
ree@antennagroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye